Brexpiprazole is a drug used to either treat Schizophrenia or to prevent its relapse. It is also approved for use as an adjuvant in the treatment of Major Depressive Disorder (MDD), as an add-on when first line antidepressants fail to provide sufficient clinical results. Brexpiprazole has been launched under the brand name Rexulti. Brexpiprazole was[…]
Brexpiprazole: A Molecule That Should Be On Your Radar
Antidepressant, Antipsychotic Tags: BrexpiprazoleSchizophrenia Mar 27, 2017
Paliperidone Approved as Quarterly Therapy for Patients with Schizophrenia
Antipsychotic, Drug Research & Development API, FDA Approved 2015 Tags: Janssen PharmaceuticalsSchizophrenia Aug 21, 2015
The FDA gave the green light in late May 2015 with their approval of a quarterly dosing schedule of Paliperidone Palmitate, also known as Invega Trinza. Marketed by Janssen Pharmaceuticals this novel dosing regimen is the first ever quarterly dosing therapy for patients with Schizophrenia. Paliperidone is dispensed to patients via an intramuscular injection every[…]
Positive Study Results for Aripiprazole Will Lead to NDA
Antipsychotic, NDA, OTC and Compounding Product Tags: Bipolar DisorderSchizophrenia Apr 18, 2014
Alkermes excitedly announced extremely positive study data from a Phase 3 trial of Aripiprazole. This randomized, placebo-controlled and double-blind study gleaned better than expected results, leading pharmaceutical executives at Alkermes to set a plan in motion for an NDA by the third quarter of 2014. As a long acting and injectable antipsychotic treatment Aripiprazole Lauroxil[…]
FDA Approves Aripiprazole As A Once A Month Treatment for Schizophrenia
Antipsychotic, Drug Research & Development API, OTC and Compounding Product Tags: antipsychoticBipolar DisorderMajor Depressive DisorderSchizophrenia Mar 06, 2013
As a blockbuster medication used to treat schizophrenia, Aripiprazole CAS# 129722-12-9 has recently been approved by the FDA as a once a month treatment. Marketed by Otsuka and Bristol-Myers Squibb, this monthly dosage of aripiprazole will be sold under the name Abilify Maintena. Aripiprazole is a solid and reliable long-acting antipsychotic medication, and this FDA[…]
Schizophrenia Patients Have an Option with Iloperidone
Antipsychotic, Drug Research & Development API, Patent Expiration 2016 Tags: antipsychoticSchizophrenia Oct 26, 2012
Iloperidone, CAS# 133454-47-4 is an antipsychotic medication. Known as the brand name Fanapt, the patent for this efficacious medication expires for Novartis on November 15, 2016. Iloperidone is available as tablets in dosages of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg, and is intended primarily for the[…]
Asenapine to Offer a Generic Option for Patients with Schizophrenia and Bipolar Disorder
Antipsychotic Tags: antipsychoticBipolar DisorderSchizophrenia Jun 20, 2012
Asenapine, also known as Saphris, marketed by Merck, is an efficacious drug for patients suffering from schizophrenia and bipolar disorder. Classified as an antipsychotic medication, Asenapine, CAS# 65576-45-6 is available in sublingual tablets of 5 and 10 milligrams. With the patent of Saphris expiring on June 8, 2015, a generic form of this lifesaving drug[…]
Risperidone Continues to Prove It's Effectiveness for Schizophrenia and Bipolar Disorder for Adults and Children
Bulk Active Ingredient, Drug Research & Development API Tags: Bipolar DisorderSchizophrenia Feb 20, 2012
Risperidone is sold under the brand name Risperdal in the United States. First developed by Janssen-Cilag, risperidone is an atypical antipsychotic that was initially released in 1994. Risperdal (risperidone) is used for patients suffering from adolescent and adult schizophrenia, schizoaffective disorder, and manic states of bipolar disorder. The FDA approved risperidone in 2003 for short[…]
